IRT-101 is an active immunotherapy with MENK for patients with deficient functioning of the immune system. It works by restoring the patient’s immune functions and by activating the lymphocytes to attack cancer cells and infectious diseases, such as HIV/AIDS. This is accomplished because MENK binds to opioid receptors on both immune cells and on cancer cells, which directly inhibits the growth of cancer cells and increases the number and functions of T cells, natural killer (NK) cells, NK-T cells, and gamma/delta T cells. These cells then destroy infective organisms and tumor cells while simultaneously inhibiting the ability of T regulatory (Treg) cells to block the functions of anti-cancer or anti-infectious disease lymphocytes.
IRT-102 is an adoptive form of immunotherapy, which involves the isolation and enrichment of a patient's own immune cells and exposes them to MENK in the laboratory. After a few days of culture, the activated lymphocytes are infused back into the patient to boost the ability of the immune system to control the cancer or infected cells.
IR-103 is an active immunotherapy with low dose naltrexone (LDN), an oral medication that works by activating a patient's immune system against HIV/AIDS and tumor cells or by rebalancing the immune system of patients with autoimmune diseases, such Crohn’s disease or multiple sclerosis (MS).
Naltrexone is FDA approved at high dose levels for the treatment of alcohol and opiate addiction because it has been shown that it has the ability to block opioid receptors in the brain and thereby help with these addictions. At a much lower dose, LDN can bind to opioid receptors on immune cells and also stimulate the production of both endogenous met-enkephalin and beta-endorphin, resulting in increased number of T cells and NK cells that destroy infectious organisms and cancer cells. LDN can also rebalance the immune system in patients with autoimmune diseases, leading to decreased tissue inflammation, repair of damaged tissue and decreased symptoms.
Our products at TNI BioTech, Inc. have the potential to treat a wide variety of diseases in which the immune system is defective or is overly aggressive against normal tissues. We have placed a high priority on investigating the following diseases, based on a substantial body of evidence from peer-reviewed publications that point to promising benefits while avoiding major side effects:
We are committed to keeping the price of our products affordable, making then an attractive complement or alternative for a large number of patients with immune deficiency of dysfunction.